The success of Sildenafil initially drove a surge for major pharmaceutical companies, nevertheless recent shifts present a complicated outlook for investors. Off-patent alternatives are eroding earnings, and continued https://neiloohf561166.slypage.com/41741169/viagra-and-pharma-a-risky-investment